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Abstract: The phosphoinositide 3-kinase (PI3-K) signaling pathway plays an important role 
in a wide variety of fundamental cellular processes, largely mediated via protein kinase B/v-akt 
murine thymoma viral oncogene homolog (PKB/AKT) signaling. Given the crucial role of 
PI3-K/AKT signaling in regulating processes such as cell growth, proliferation, and survival, 
it is not surprising that components of this pathway are frequently dysregulated in cancer, 
making the AKT kinase family members important therapeutic targets. The large number of 
clinical trials currently evaluating PI3-K pathway inhibitors as a therapeutic strategy further 
emphasizes this. The serum- and glucocorticoid-inducible protein kinase (SGK) family is made 
up of three isoforms, SGK1, 2, and 3, that are PI3-K-dependent, serine/threonine kinases, with 
similar substrate specificity to AKT. Consequently, the SGK family also regulates similar cell 
processes to the AKT kinases, including cell proliferation and survival. Importantly, there is 
emerging evidence demonstrating that SGK3 plays a critical role in AKT-independent oncogenic 
signaling. This review will focus on the role of SGK3 as a key effector of AKT-independent 
PI3-K oncogenic signaling.
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Introduction
The phosphoinositide 3-kinase (PI3-K) pathway integrates signals from growth factors, 
insulin, nutrients, and oxygen to initiate a plethora of downstream responses. This 
pathway is frequently dysregulated in human cancer and regulates many of the hallmarks 
of cancer,1 including cell growth, proliferation, survival, migration, metabolism, and 
angiogenesis, as shown in Figure 1; thus, it is a pivotal target for cancer therapy.2–4 
To date, much of the evidence gathered supporting PI3-K as a critical modulator of 
tumor formation and progression has revealed the main downstream effector to be the 
v-akt murine thymoma viral oncogene homolog (AKT) family of kinases (AKT1, 2, 
and 3), with all three AKT isoforms playing both overlapping and distinct roles in cell 
transformation and tumorigenesis.5 However, despite this paradigm for PI3-K-dependent 
transformation via AKT, there are multiple alternative oncogenic pathways, such as 
mitogen-activated protein kinase (MAPK) cascade, liver kinase B1 (LKB1) and v-myc 
myelocytomatosis viral oncogene (MYC), that interact with the core PI3-K signaling 
module both upstream and downstream of AKT.6–9 The importance of the PI3-K pathway 
in a number of cancer types has been well established,10–12 with genetic defects leading 
to the hyperactivation of the PI3-K cascade occurring in many cancers.
Despite AKT signaling being a major downstream effector of PI3-K signaling, there 
is mounting evidence to suggest the importance of other signaling factors downstream 
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of PI3-K that act independently of AKT to mediate important 
cell processes that are involved in malignant transformation. 
Recent studies focusing on 3-phosphoinositide-dependent 
kinase 1 (PDK1), an immediate downstream effector of 
PI3-K (as illustrated in Figure 1), have demonstrated that 
in some tumor models, following knockdown of PDK1, the 
overexpression of activated AKT is not enough to restore 
malignant phenotypes, suggesting a subset of tumors 
that are PI3-K/PDK1-dependent but AKT-independent.13 
Further, many of these studies have also demonstrated that in 
malignancy driven by AKT-independent factors, expression 
of activated AKT is quite low and correlates poorly with 
PIK3CA oncogenic mutations.14,15 Together, these studies 
indicate the presence of a PI3-K/PDK1 downstream target 
capable of driving oncogenic signaling independently of the 
AKT kinases, and active in a subset of tumors.
PI3-K activation of PDK1 can induce the activity of 
several protein kinases, including protein kinase C zeta 
and the serum- and glucocorticoid-inducible protein kinase 
(SGK) isoforms, all of which have the potential to contribute 
to the tumorigenic phenotype.16 The PI3-K pathway leads 
to activation of the SGK isoforms, in a PDK1-dependent 
manner, promoting SGK isoform expression and activity.17 
All three isoforms of SGK share high structural and 
functional similarities to the AKT kinases, with many 
studies demonstrating the SGK isoforms have important 
roles in PI3-K signaling, both in normal cell physiology and 
pathophysiology.18,19 Recently, there have been a number 
of reports that implicate SGK3 as a critical mediator of 
malignant transformation independently of AKT.20,21 Thus, 
this review will focus on SGK3 as an alternate signaling 
effector of PI3-K in tumorigenesis.
PI3-K signaling
The PI3-K family is integral in a variety of cellular processes, 
coordinating the localization and activity of a multitude of 
important downstream effector proteins, including the SGK 
and AKT families of kinases. The PI3-K family is made up 
of three distinct classes (class I, II, and III), all of which are 
grouped according to structure, function, and lipid substrate 
preference.3 The class I PI3-K family can be further divided 
into class IA and IB, both of which are heterodimers made 
up of a catalytic subunit and a regulatory subunit. Class 1A 
PI3-K are made up of one of the three different p110 catalytic 
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Figure 1 PI3-K signaling.
Notes: Activation of class I PI3-K via RTK phosphorylates and activates downstream target PDK1, in turn phosphorylating AKT kinases at the threonine site. Full activation of 
AKT requires phosphorylation at the serine residue by the mTORC2. Activated AKT mediates a plethora of effects through phosphorylation of a number of downstream targets 
including TSC2 and PRAS40. Additional factors such as HIF1α, LKB, c-MYC and the RAS signaling pathway are also able to link into PI3-K signaling at multiple levels and contribute 
to protein synthesis and cell growth signaling. At the endosome, class III PI3-K hVps34 is able to mediate amino acid signaling to mTORC1.
Abbreviations: AKT, v-akt murine thymoma viral oncogene homolog; AMPK, 5′ AMP-activated protein kinase; HIF1α, hypoxia-inducible factor 1 alpha; hVps34, class III PI3-K 
human vacuolar sorting protein 34; LKB, liver kinase B1; mTORC1, mammalian target of rapamycin complex 1; mTORC2, mammalian target of rapamycin complex 2; PDK1, 
3-phosphoinositide-dependent kinase 1; PI3-K, phosphoinositide 3-kinase; PRAS40, proline-rich AKT substrate of 40 kDa; PTEN, phosphatase and tensin homolog; RTK, receptor 
tyrosine kinases; TSC1, tuberous sclerosis factor 1; TSC2, tuberous sclerosis factor 2; Rheb, Ras homolog enriched in brain; REDD1, DNA damage inducible transcript 4; eIF4E, 
eukaryotic translation initiation factor 4E; 4EB-P1, eukaryotic translation initiation factor 4E binding protein 1; rpS6, ribosomal protein S6.
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subunits (p110α, p110β, and p110δ), all products of separate 
genes (PIK3CA, PIK3CB, and PIK3CD, respectively), and 
one of the five p85 regulatory subunits (including p85α, 
p55α, and p50α), all of which are splice variants of a single 
gene (PIK3R1), with the remaining two p85 variants (p85β 
and p55γ) both products of separate genes (PIK3R2 and 
PIK3R3), respectively.22
The class IB PI3-K family can be distinguished from IA, 
as the catalytic subunit p110γ, encoded by gene PIK3CG, 
does not bind p85 regulatory subunit but instead binds 
regulatory subunits p101 or p87, encoded by genes PIK3R5 
and PIK3R6, respectively. The inability to bind the p85 
regulatory subunit has upstream signaling consequences 
in that p85 regulatory subunit contains Src homology 2 
domains (SH2), which are able to bind phosphorylated 
tyrosine, correlating with its ability to be activated through 
receptor tyrosine kinases (RTKs), therefore enabling class 
IA to be activated by RTKs, and class 1B to be activated by 
G protein–coupled receptors (GPCR). Both class IA and 1B 
can be activated indirectly by RAS.23
Canonical signaling via the class I PI3-K is activated by 
growth factor RTKs in addition to G-protein-coupled receptors. 
Once activated, PI3-K phosphorylates phosphoinositides, 
generating the lipid products phosphatidylinositol-3-4-
bisphosphate (PI(3,4)P
2
) and phosphatidylinositol-3,4,5-
triphosphate (PI(3,4,5)P
3
), allowing PI(3,4,5)P
3
 to recruit 
Pleckstrin Homology (PH) domain–containing proteins to 
the plasma membrane, such as PDK1 and AKT, for activation 
via phosphorylation at key residues.24–26 Once at the plasma 
membrane, PDK1 is able to phosphorylate and fully activate 
AKT at threonine 308 following phosphorylation of AKT at the 
serine 473 site by mTORC2 (mammalian target of rapamycin 
complex 2).27 Activated AKT has many downstream targets, 
implicating PI3-K/AKT signaling in processes such as cell 
growth, proliferation, survival, metabolism, and angiogenesis.
Additionally, a number of other important pathways 
involved in malignant transformation have also been reported 
to intersect and cooperate with PI3-K signaling downstream 
of AKT, including energy sensing via LKB1,28 mitogens 
via MAPK, hypoxia via regulated in development and 
DNA damage responses 1 (REDD1), and c-Myc, as shown 
in Figure 1.1,9 Further, reports demonstrate that nutrient 
signaling via the endosomally localized class III PI3-K 
human vacuolar sorting protein 34 (hVps34) is involved in 
mTOR regulation downstream of AKT. While both the SGK 
and AKT kinases have shown to be phosphorylated and 
activated in a class I PI3-K-dependent manner, the SGK3 
kinase through its N-terminal phox homology (PX) domain 
is localized to the endosome. Consequently, investigation 
into a possible interaction between hVps34 and SGK3 at the 
endosome may link SGK3 with mediating nutrient signaling 
via mTOR complex 1 (mTORC1).
Class I PI3-K
The class IA PI3-K signaling cascade is a crucial modulator 
linking the activation of multiple receptor classes to many 
core cell processes, including cell cycle, cell survival, protein 
synthesis, growth, metabolism, motility, and angiogenesis, 
via key signaling intermediates, including the SGK and AKT 
families.22,29 Numerous reports have demonstrated an active 
role for this pathway in many types of human cancers, with 
one or more of its signaling components exhibiting constitutive 
activation due to a genetic aberration, which ultimately leads to a 
malignant phenotype.2,24 Dysregulation of several components of 
the PI3-K pathway, including PI3-K itself, PTEN (phosphatase 
and tensin homolog), and AKT, have been demonstrated in 
human cancer, with probably the most prevalent affecting the 
PIK3CA gene and tumor suppressor PTEN.30 Furthermore, 
receptor tyrosine kinases such as epidermal growth factor 
receptor (EGFR), human epidermal growth factor receptor 2 
(HER2), and platelet-derived growth factor receptor (PDGFR) 
are often up-regulated in human cancer and engage the PI3-K 
pathway via interaction with the p85 regulatory subunit.31–33
The PIK3CA gene, located on chromosome 3, encodes for 
the p110α subunit of class IA PI3-K, and is either mutated or 
amplified in a number of different cancer types.34–36 PIK3CA 
knockout mouse embryonic fibroblasts are deficient in cellular 
signaling in response to various growth factors, and resistant 
to oncogenic transformation induced by RTKs,37 together 
demonstrating that PI3-K is involved in growth factor signaling 
and fundamental to tumorigenesis. The somatic missense 
mutations affecting the PIK3CA gene have been mapped to 
hotspot regions, exon 9, which encodes the helical domain of 
p110α, and exon 20, which encodes the catalytic domain of 
p110α.38,39 These mutations constitutively activate AKT through 
increased production of PI(3,4,5)P
3
 and induce oncogenic 
transformation both in vitro and in vivo.30,40–45 In addition to 
the frequent hot spot mutations, almost 100 rare mutations 
have also been identified in PIK3CA.46,47 The PIK3R1, which 
encodes for the p85 subunit of PI3-K, also exhibits mutations 
in colorectal and ovarian cancers, which result in overactivity 
of PI3-K signaling through loss of p85 subunit inhibition of the 
p110 catalytic subunit of PI3-K.40,48 Class II PI3-K comprises 
three catalytic isoforms (C2α, C2β, and C2γ) which generate 
both phosphatidylinositol 3-phosphate (PI(3)P) and PI(3,4)
P
2
,49 and while PI(3)P localizes SGK3 to the endosome, it is 
the class I PI3-K that have shown to be associated with SGK3 
activation. Further, the class III PI3-K hVps34, has shown to 
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be localized at the endosome in addition to producing PI(3)-P 
only, making it a potential candidate for mediating SGK3 
function at the endosome. Thus, both class I and class III 
PI3-K are likely to be the most relevant of the PI3-K classes 
in SGK3 activation and function.
Class III PI3-K
The class III PI3-K family consists of only one catalytic 
subunit, hVps34, localized at the early endosome, which 
was originally identified in a screen for genes involved in 
endosomal sorting in Saccharomyces cerevisiae.50 hVps34 
forms a constitutive heterodimer with Vps15, and has shown 
a limited substrate specificity of only inositol-containing 
lipids (PtdIns), thereby producing a single lipid product 
phosphatidylinositol 3-phosphate (PI(3)P), allowing it 
to function in the recruitment of proteins containing 
PI(3)P binding domains (PX domains) to intracellular 
membranes.50–52 Many studies have demonstrated an 
important role for hVps34 in vesicular trafficking in the 
mammalian endosomal system,53 with stable hVps34 
knockdown blocking the formation of multivesicular body 
formation, and slowing receptor degradation. However, more 
recent studies in mammalian systems have also recognized 
that hVps34 is involved in autophagy through association 
with Beclin-1, and nutrient sensing through signaling to 
mTOR.54–57 hVps34 has shown involvement in the regulation 
of the mTOR pathway through studies involving hVps34 
knockdown, which demonstrated a block in insulin-stimulated 
phosphorylation of both S6 kinase 1 (S6K1) and eukaryotic 
initiating factor 4E binding protein 1 (4EB-P1), both key 
downstream effectors in the mTORC1 growth signaling 
pathway and readouts of mTORC1 activity.50 Further, 
overexpression of hVps34 activates S6K1 in the absence of 
insulin stimulation; conversely, hVps34 knockdown blocks 
amino acid stimulation of S6K1.
Growth factor regulated pathways leading to the 
activation of mTORC1 via AKT have been extensively 
characterized, while the mechanisms by which nutrients are 
able to activate mTORC1 remains ill-defined.57 Earlier studies 
have demonstrated that amino acid-dependent activation of 
mTORC1 requires the Rag guanosine triphosphate (GTP)
ases,58,59 while additional studies have implicated other 
proteins, including MAP4K3 (mitogen-activated protein 
kinase kinase kinase kinase),60 and inositol polyphosphate 
monokinase (IMPK);61 however, how these molecules interact 
to mediate nutrient signaling requires further investigation. 
The class III PI3-K hVps34 has also been implicated in 
nutrient signaling to mTORC1; this regulation is dependent 
on the associated kinase hVps15 and independent of TSC 
(tuberous sclerosis complex).54,55 The ability of SGK3 to 
selectively bind PI(3)P, targeting it to the early endosomes 
where it is fully activated, suggests a pool of endosomally 
localized upstream signaling factors such as class I PI3-K 
and PDK1 may be available for SGK3 activation.19 The 
class III PI3-K hVps34 has not been shown to be directly 
involved in SGK3 signaling; however, endosomally localized 
hVps34 mediates nutrient signaling to mTOR and specifically 
generates the lipid product PI(3)P, while SGK3 binds 
PI(3)P, allowing it to be localized to the endosome, where 
it is activated and can signal to growth via mTORC1. Thus, 
it is plausible that a growth signaling connection may exist 
between hVps34 and SGK3, contributing to oncogenic cell 
growth during cell transformation and tumorigenesis. If so, 
this would represent an important new aspect to understanding 
AKT-independent regulation of nutrient signaling.
AKT as an established effector 
of PI3-K signaling
The PI3-K/AKT pathway has been identified as a crucial 
node of growth and proliferation through the ability of AKT 
to regulate mTORC1, which mediates the coordinate growth 
factor and nutrient signaling. mTORC1, through convergence 
on downstream targets S6K and 4EB-P1, regulates core growth 
processes, including ribosome biogenesis, transcription, 
translation initiation, and protein degradation.62–65 Many 
studies have identified AKT as an important modulator of 
mTORC1, and thus cell growth and proliferation. As shown in 
Figure 1, AKT phosphorylates the tumor suppressor tuberous 
sclerosis factor 2 (TSC2), a crucial negative regulator of 
mTORC1, at two distinct sites (serine 939 and threonine 
1462), thereby inhibiting TSC2 function and promoting 
mTORC1 activation.4,66,67 Furthermore, AKT has also been 
shown to phosphorylate a proline-rich AKT substrate of 
40 kDa (PRAS40), a protein associated with mTORC1. 
Phosphorylation of PRAS40 at threonine (Thr)246 by AKT 
prompts its dissociation from mTORC1 and subsequently 
indirectly activates mTORC1 signaling.68,69 In addition, 
many reports demonstrate a role for AKT in cell proliferation 
through the regulation of cyclin dependent kinase (CDK) 
inhibitors and glycogen synthase kinase β (GSK3β) via PI3-K 
signaling,70 in addition to cell survival through regulation of 
forkhead transcription factor 3a (FOXO3a),71 Bcl-2 associated 
death promoter (BAD),72 murine double minute 2 (MDM2),73 
and the nuclear factor κB (NF-κB) pathway.74 AKT can also 
directly modulate ribosome biogenesis independent of TOR, 
thus promoting growth and proliferation.75
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Much of the aberrant regulation through the PI3-K 
pathway observed in tumorigenesis is associated with 
hyperactivation of AKT. Although dysregulation of upstream 
signaling stimulates AKT activity, the akt1 gene has also 
found to be amplified, in head and neck, gastric, pancreatic, 
and ovarian tumors.76–78 Furthermore, a missense mutation 
identified in the pleckstrin homology domain of akt1 has 
been described at low frequency in breast, colorectal, and 
ovarian cancers,79 which leads to targeting of AKT1 to the 
plasma membrane, constitutive activation of the kinase 
and enhanced downstream signaling. Genetic aberrations 
associated with akt2 and akt3 have also been reported, with 
akt2 frequently amplified in ovarian and breast cancer,77 along 
with an activation of AKT2 kinase activity in approximately 
36% of ovarian tumors.80 An increase in akt3 copy number 
has also been observed in approximately 70% of sporadic 
melanomas,81 and AKT3 has shown to be overexpressed 
in 19 of 92 primary ovarian tumors, showing up to tenfold 
higher specific activity than AKT1, potentially amplifying 
any effect of AKT3 overexpression.82 Further, an analysis of 
frequency for which 316 advanced-stage high-grade serous 
ovarian cancers harbored one or more mutations, copy 
number changes or changes in gene expression in the PI3-K/
rat sarcoma viral oncogene homolog (RAS) pathway were 
shown to be deregulated in 45% of cases,83 demonstrating the 
importance of this pathway in oncogenic pathophysiology.
AKT-independent PI3-K signaling 
to cancer
While AKT is considered to be the key downstream effector 
of PI3-K oncogenic signaling, there have been a number 
of recent studies demonstrating that in many cases there is 
an AKT-independent signaling node that also contributes 
to malignant transformation. A recent study to investigate 
the role of PDK1 in tumor progression using breast cancer 
cell lines harboring either PIK3CA or KRAS gain of func-
tion mutations demonstrated that PDK1 knockdown led to 
increased anoikis, reduced anchorage independent growth, 
and apoptosis in breast tumors. Interestingly, the expression 
of activated AKT was unable to rescue the PDK1-dependent, 
anchorage-independent growth phenotype, suggesting a 
PDK1-dependent, AKT-independent signaling node in breast 
cancer.13 Furthermore, a model of human ovarian endo-
metrioid adenocarcinoma, based on somatic defects in the 
wingless-related MMTV integration site (Wnt)/β-Catenin 
and PI3-K/PTEN signaling pathways,84 demonstrated equiv-
alent pPDK1 and phospho ribosomal protein S6 (pRPS6) 
levels but relatively low levels of pAKT,14 suggesting that 
these mutations may drive tumor formation via an AKT-
independent mechanism. Similarly, prostate-specific loss of 
PTEN in a murine model resulted in tumors with elevated 
AKT and mTORC1 activity. However, surprisingly, the 
inhibition of AKT resulted in little effect on tumor growth, 
implying that PI3-K-dependent but AKT-independent sig-
naling was driving tumorigenesis.85 Furthermore, in both 
breast and ovarian cancers, AKT activity has been shown 
to correlate poorly with PIK3CA mutations,15 suggesting 
alternative PI3-K-dependent mediators of tumorigenesis 
driven by mutant PIK3CA.
It has been proposed that the SGK protein isoforms 
are likely candidates for PI3-K signaling to tumorigenesis, 
independent of AKT, given that they play roles in cell 
survival, proliferation, and growth, and share many of the 
same substrates with AKT.18 The most convincing data to 
support this hypothesis comes from studies performed using a 
lentiviral short hairpin RNA (shRNA) library targeting .1000 
kinases, phosphatases, and other cancer genes. Using this 
library to screen PIK3CA mutant tumor cells with minimal 
AKT activation, SGK3 was identified as a PDK1 substrate 
that conferred increased cell viability. Furthermore, these cells 
had a critical reliance on SGK3 for anchorage independent 
growth,21 thus indicating that in the absence of AKT signaling 
SGK3 is able to drive certain aspects of malignant cell 
transformation. Another study examining SGK3 expression in 
estrogen receptor–positive breast tumors identified a positive 
correlation between SGK3 level and patient survival and 
prognosis, where previous analyses had not found a correlation 
between AKT messenger (m)RNA expression and tumor 
prognosis.86,87 These observations suggest that SGK3 may be 
an important downstream effector for many breast and ovarian 
cancers harboring PIK3CA mutations and reduced AKT 
signaling, and thus a potential alternative therapeutic target for 
the treatment of these malignancies. Furthermore, they also 
raise the possibility that SGK activation is a mechanism of 
resistance to AKT inhibitors. Indeed, recent studies in breast 
cancer cell lines show cells that express high levels of SGK1 
were resistant to AKT inhibition.88
SGK3 has also been identified as a crucial effector of 
PI3-K/AKT-independent signaling in the pathogenesis 
of hepatocellular carcinoma (HCC). Amplification and 
overexpression of SGK3 is more common than AKT in HCC, 
suggesting it may have a greater functional significance in 
the biology of this cancer. For example, HCC tumor tissue 
demonstrated a significant increase in SGK3 transcript 
expression when compared with paired nontumor tissue. 
Moreover, in vitro functional assays demonstrated that 
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enforced expression of SGK3 was able to increase cell 
growth, colony formation, and anchorage-independent 
growth in HCC cells, while SGK3 knockdown was able 
to significantly decrease these processes.20 Furthermore, 
xenograft models overexpressing SGK3 in a human HCC 
cell line demonstrated tumor formation in four out of the 
five mice injected, while mice injected with empty vector 
cell lines exhibited no tumor growth in any mice. Finally, 
overexpression of SGK3 significantly correlates with poor 
overall survival of HCC patients (P = 0.028).20 However, in 
contrast to these studies demonstrating a role for SGK3 in 
AKT-independent oncogenic signaling, a recent report failed 
to demonstrate a role for SGK3 in mediating aberrant PI3-K 
activity in a panel of ovarian tumor samples exhibiting 
low AKT activation.89 Specifically, tumors presenting with 
low phosphorylated AKT but with high PIK3CA, SGK3 
activation was detected in only 36% of ovarian tumors, and 
SGK3 phosphorylation did not correlate with phosphorylated 
PIK3CA overexpression or AKT activation. Further, activated 
SGK3 was detected in only three out of the nine ovarian 
tumors that were positive for phosphorylated PIK3CA and 
negative for phosphorylated AKT, suggesting that while 
SGK3 is likely not implicated in all aberrant PI3-K oncogenic 
signaling, it is consistent with SGK3 playing a role in a subset 
of tumors. Clearly, further studies in larger patient cohorts are 
required to more definitively delineate the role of SGK3 in 
aberrant PI3-K oncogenic signaling.
SGK3 – a unique member 
of the SGK family
Studies using murine interleukin-3 (IL-3)-dependent 32D 
cells identified the mouse homolog of human SGK3, known 
as cytokine independent survival kinase (CISK), in a genetic 
screen to identify factors that mediate IL-3-dependent survival 
of hematopoietic cells.90 Several splice variants for sgk3 have also 
been identified. The human gene encoding sgk3 (also referred to as 
sgk-l (serum/glucocorticoid regulated kinase-like)) is localized to 
chromosome 8q12.2;91 it is ubiquitously expressed at the mRNA 
level, although mRNA abundance can vary considerably from 
tissue to tissue (www.genecards.org). Although constitutively 
expressed, sgk3 has estrogen receptor–binding regions and can 
be transcriptionally induced with estrogen.92
SGK3 is unique within the SGK family as it contains 
an N-terminal PX domain, as shown in Figure 2, initially 
shown to be important for targeting SGK3 to vesicle-like 
structures.90 The PX domain in many proteins acts as a 
specific phosphoinositide-binding module, which has varying 
lipid-binding specificities. The most common binding 
specificity for the PX domain appears to be for PI(3)P; hence, 
several PX domain-containing proteins localize to PI(3)P-rich 
endosomal and vacuolar structures through this domain.93 
SGK3 binds strongly and selectively to PI(3)P through its 
PX domain, which is required for targeting SGK3 to the 
endosomal compartment.94 Mutation of the SGK3 PX domain 
at the phospholipid binding pocket diminishes phospholipid 
binding, endosomal localization, and SGK3 activity.95 SGK3 
localization and activation at the endosome is also discussed 
in the Class III PI3-K section.
The catalytic domain of SGK3 shares significant amino 
acid identity with the AKT kinases,96 and importantly contains 
a functional serine/threonine protein kinase domain, which 
includes lysine 191 in the adenosine triphosphate (ATP) 
binding site and threonine 320 in the activation loop. Both of 
these sites require phosphorylation for full catalytic activity.97 
The C-terminal hydrophobic domain of SGK3 contains a 
second phosphorylation site, serine 486, which is required 
for complete kinase activation.96 There is evidence that 
mTOR complex 2 (mTORC2) controls the phosphorylation 
of SGK1’s hydrophobic motif and thus its activation.98–100 
While the kinase responsible for phosphorylation of 
SGK3 at the homologous serine (Ser) residue within the 
hydrophobic motif remains undefined, the strong sequence 
conservation in this domain among the SGK isoforms 
indicates it is also likely to be mTORC2. The development 
of reliable phospho-specific SGK3 antibodies would assist 
in further characterizing the role of mTORC2 in SGK3 
regulation. All SGK isoforms are enzymatically activated via 
phosphorylation in a PI3-K-dependent manner.101,102 SGK3 
phosphorylation and activation has shown to be stimulated 
by oxidation, insulin and insulin growth factor 1 (IGF-I),94,103 
and specifically by IL-390 and estrogen.92
While studies have demonstrated that SGK3 is activated 
in a class I PI3-K-dependent manner via PDK1, to date there 
N-terminal Catalytic C-terminal 
S486 T320 
Activation loop Hydrophobic motif
R90
Phox homology
domain
PIP3 binding P P
Figure 2 The SGK3 protein domain structure.
Notes: SGK3 variants containing a PX domain in the N-terminal region between 
amino acids 12–120, allowing SGK3 to bind to PI(3)P, and localize to the early 
endosomes. SGK3 has two key regulatory sites, consisting of Serine 486 in the 
C-terminal hydrophobic motif and Threonine 320 in the activation loop of the 
catalytic domain, both of which require phosphorylation for complete activation.
Abbreviations: PI(3)P, phosphatidylinositol 3-phosphate; PX, phox homology; 
SGK3, serum and glucocorticoid inducible kinase 3; T, threonine; S, serine.
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have been no reports demonstrating that the class III PI3-K 
family directly or indirectly interacts with SGK3. However, 
the unique localization of SGK3 at the early endosomes, 
where the class III PI3-K family catalytic subunit hVps34 
resides, raises the possibility that SGK3 may potentially 
modulate nutrient signaling via interaction with hVps34, in 
a manner independent of AKT. In support of this, increases 
in intracellular amino acid levels such as leucine have shown 
an increase in phosphorylation of mTORC1 effectors, 
S6K1 and 4EB-P1, independent of AKT.104 Furthermore, 
overexpression of hVps34 activates S6K1 in the absence of 
insulin stimulation, and conversely hVps34 knockdown blocks 
amino acid stimulation of S6K.50 In the endosome, hVps34 is 
able to produce PI(3)P, thereby recruiting proteins containing 
PI(3)P-binding domains, such as Fab1/ metallo-dependent 
hydrolase (YOTB)/2K632.12/Vac1/early endosomal antigen 
1 (EEA1) and PX domains, many of which are involved in 
vesicular trafficking and receptor sorting, as discussed in the 
Class III PI3-K section earlier. Indeed, SGK3 has shown to be 
involved in receptor sorting at the endosome through regulating 
the degradation of the E3 ligase atrophin-1 interacting protein 
4 (AIP4), important for degradation of the chemokine (C-X-C 
motif) receptor 4 (CXCR4).105 Thus, while it is plausible that 
SGK3 may also play a role in mediating hVps34-dependent 
regulation of protein synthesis via mTOR/S6K1, further studies 
are required to elucidate this connection.
The substrate specificities for the SGK family have been 
determined through a panel of synthetic peptides, and dem-
onstrate that they preferentially phosphorylate serine and 
threonine residues within the Arg-Xaa-Arg-Xaa-Xaa-Ser/
Thr-ϕ motifs, (where Xaa stands for any amino acid),101,106–108 
similar to the substrate specificity of the AKT family.96 Char-
acterization of SGK3 substrate specificity has shown that it 
tolerates the presence of lysine instead of arginine at position 
n-3.96 This difference is consistent with the ability of SGK3 
to target substrates such as AIP4105 and flightless-I (FLI-I),109 
which are not SGK1 or SGK2 substrates.
A more comprehensive investigation into the role of 
SGK3 has been achieved through the generation of various 
sgk gene knockout mice. Characterization of sgk3-/- mice 
demonstrated a distinct defect in hair follicle morphogenesis, 
producing a wavy hair phenotype. Further analysis revealed a 
defect in proliferation and nuclear accumulation of β-catenin 
in hair-bulb keratinocytes; however, these mice exhibited 
normal sodium and glucose handling.110,111 Interestingly, 
a profound proliferation defect has also been reported in 
pik3cadel/del embryos, which show to die between E9.5 and 
E10.5.112 A double sgk1-/-/sgk3-/- mouse has also been 
generated, and exhibited the combined phenotype of sgk1-
/- and sgk3-/- mice, displaying a wavy hair phenotype and 
impairment of renal Na+ retention on a low-salt diet.113 These 
studies using both single and double knockout animals have 
assisted in determining possible functional redundancies 
within the SGK family, with both sgk1-/- and sgk3-/- single 
knockout mice exhibiting quite different phenotypes.
The combined knockout of both sgk1 and sgk3 did not 
produce a more severe phenotype, suggesting that these 
two isoforms most likely do not compensate for each other. 
However, it is possible that the phenotype of the sgk1-
/-/sgk3-/- mouse is not more severe as SGK2 may be able to 
compensate and maintain some level of homeostasis, despite 
no detectable increase of SGK2 transcript levels in these 
mice.113 Characterization of an akt2-/-/sgk3-/- mouse found 
that the defect in hair growth is markedly worse in the double 
knockout mice than in sgk3-/- mice only114 and that they have 
a markedly greater impairment of glucose homeostasis than 
Akt2-/- mice.115 Akt2-/- mice also displayed insulin resistance, 
hyperinsulinemia and increased β-cell proliferation and 
mass.116 These studies demonstrate that these proteins have 
both unique and common cellular functions, and in some 
cases work in parallel to augment the effect.
SGK3 as a key effector of PI3-K 
signaling
The dysregulation of many SGK3 downstream targets 
has been associated with important processes such as cell 
proliferation, growth, survival, and migration, all of which 
contribute to malignant transformation, as illustrated in 
Figure 3. Furthermore, while SGK3 and AKT kinases 
exhibit very similar substrate specificities, they can also 
target distinct residues on individual substrates that affect 
these processes. For example, phosphorylation of FOXO3a, 
a member of the forkhead transcription factor family 
involved in the induction of cell cycle arrest and apoptosis, 
is phosphorylated by both AKT and SGK3 on different sites, 
and this results in a synergistic response.90,110,117 This example, 
in addition to the evidence demonstrating clear differences in 
cellular localization between these kinase families, indicates 
the potential for SGK and AKT to have complementary roles 
as downstream effectors of PI3-K. Additionally, the akt2-/-/
sgk3-/- double knockout studies show a level of functional 
redundancy between SGK3 and AKT2, indicating that these 
kinases may be able to compensate for each other where 
required. Further studies using additional akt and sgk3 double 
knockout models will assist in further delineating similarities 
between these kinase families.
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Hallmark of cancer – cell proliferation
SGK3 potentially plays an important role in cell proliferation, 
through its ability to indirectly regulate the CDK inhibitor 
p27Kip1 via modulation of forkhead transcription factors. 
The regulation of FOXO3a by SGK3 occurs via SGK-
dependent phosphorylation of FOXO3a at multiple sites, and 
ultimately prevents FOXO3a from localizing to the nucleus 
to affect its targets. In addition to transcriptional regulation 
of p27Kip1, the FOXO proteins are also involved in the 
regulation of other cell cycle machinery, including CDK4, 
cyclin D1, and retinoblastoma members p107 and p130;118 
thus, SGK3 regulation of FOXO3a is likely to impact cell 
cycle regulation at multiple levels. SGK3 also modulates 
GSK3β. GSK3β is involved in the regulation of numerous 
physiological processes, including the phosphorylation of 
cyclin D1, important in cell cycle transition. Following 
phosphorylation by GSK3β, cyclin D1 is marked for 
degradation by the proteasome,11 and similar to AKT, SGK3 
can phosphorylate and inactivate GSK3β, allowing cyclin D1 
to continue its role in the cell cycle.103,119
Hallmark of cancer – cell growth
The AKT kinases regulate cell growth at multiple levels; 
the best characterized pathway is via signaling through 
mTORC175,120,121 by its phosphorylation and inhibition of 
TSC2 and PRAS40. While few studies have definitively 
demonstrated a role for SGK3 in the control of cell growth, 
recent studies in our laboratory have shown a role for 
SGK3 in growth signaling through increasing phosphorylated 
TSC2, PRAS40, ribosomal protein S6 (rpS6), and 4EB-P1 in 
normal cell physiology and malignant transformation.18
Hallmark of cancer – cell survival
There have been a number of studies highlighting the 
role of SGK3 in cell survival. In addition to mediating 
IL-3-dependent survival of 32D and BAF3 hematopoietic 
cells,90 SGK3 as well as SGK1 negatively regulate activity of 
the proapoptotic FOXO transcription factor FOXO3a, and can 
increase the level of BAD and thus attenuate cell death via 
B-cell CLL/lymphoma 2 (BCL-2).90 SGK3 is also involved 
in cell survival signaling in estrogen receptor–positive breast 
cancer cells,92 potentially via FLI-I a downstream target of 
SGK3,109 which acts as a coactivator for the estrogen receptor, 
enhancing receptor activity, and promoting proliferation and 
survival. In addition, SGK3 is transcriptionally regulated by 
estrogen receptor;92 thus, a positive feedback loop between 
SGK3 and the estrogen receptor potentially exits, which 
may play an important role in estrogen signaling in estrogen 
receptor–positive breast cancer, highlighting a crucial role 
for SGK3 in cell survival signaling.
Hallmark of cancer – cell migration
There are a limited number of studies that have addressed 
the role of SGK3 in cell migration. The phosphorylation 
and subsequent inactivation of GSK3β by SGK3 has been 
implicated with alteration of β-catenin dynamics, leading to 
the formation of adherens junctions and tight junction sealing 
in mammary epithelial cells,122 raising the possibility that 
SGK3 may be involved in cell polarity and migration. Further, 
characterization of the sgk3-/- mouse exhibited a wavy hair 
phenotype, with further analysis revealing disorganization 
of hair follicles and cells in the outer root sheath, suggesting 
dysregulation of cell polarity.110,111 SGK3 also negatively 
regulates the lysosomal degradation of the CXCR4, whose 
signaling is strongly associated with the promotion of cell 
invasion, migration, and adhesion during metastasis in breast 
cancers.123,124 SGK3 was also shown to be able to colocalize, 
interact, and phosphorylate the E3 ubiquitin ligase AIP4 in 
the early endosomes, thereby specifically attenuating the 
ubiquitin-dependent degradation of CXCR4.105 Together, these 
studies indicate a connection between SGK3 and cell migration 
and polarity; however, further studies are required to more 
specifically characterize the role of SGK3 in these processes.
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Figure 3 PI3-K signaling via SGK3 and AKT.
Notes: Activation of PI3-K by growth factor receptors leads to phosphorylation of 
PDK1, subsequently leading to phosphorylation and activation of AKT and SGK3. 
Following activation these kinases have shown to regulate TSC2 and PRAS40, 
leading to activation of mTORC1, an important node in signaling to protein synthesis 
and cell growth. In addition, AKT and SGK3 regulate FOXO3a, BAD, and GSK3β, 
allowing regulation of cell survival. SGK3 is also able to regulate AIP4 and FLI-I, 
affecting cell migration and cell survival, respectively.
Abbreviations: AIP4, atrophin-1 interacting protein 4; AKT, v-akt murine thymoma 
viral oncogene homolog; BAD, Bcl-2 associated death promoter; FLI-I, flightless-I; 
FOXO3a, forkhead transcription factor 3a; GSK3β, glycogen synthase kinase β; 
hVps34, class III PI3-K human vacuolar sorting protein 34; mTOR, mammalian target 
of rapamycin; mTORC1, mammalian target of rapamycin complex 1; mammalian 
target of rapamycin complex 2; PDK1, 3-phosphoinositide-dependent kinase 1; PI3-K, 
phosphoinositide 3-kinase; PRAS40, proline-rich AKT substrate of 40 kDa; PX, phox 
homology; SGK3, serum and glucocorticoid inducible kinase 3; TSC2, tuberous sclerosis 
factor 2; PTEN, phosphatase and tensin homolog; mLST8, MTOR associated protein 
LST8 homolog; mSIN1, mitogen-activated protein kinase associated protein 1.
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Conclusion and future directions
The PI3-K pathway is regarded as one of the most crucial for 
cancer development and maintenance, with the ubiquitous 
nature of PI3-K pathway activation making both upstream 
and downstream components of the PI3-K signaling pathway 
attractive therapeutic targets. Currently, in clinical trials, there 
are around 30 small molecule and other inhibitors that target 
this pathway. The recent reports of functional dependency 
of PI3-K signaling on SGK3 in cancer highlights the ability 
of SGK3 to act as an alternate, AKT-independent signaling 
pathway capable of transducing critical cell proliferation 
and survival signals, and indicates that SGK3 may offer 
another avenue for targeted therapy. Further investigation 
into SGK3 signaling in both normal cell physiology and 
pathophysiology will require studies using inducible small 
interfering RNA systems, along with the development 
of specific small molecule inhibitors to further delineate 
the role of SGK3 signaling in malignant transformation. 
Currently, two small molecule inhibitors have been designed 
to target SGK1, suggesting that inhibitors for other members 
of this kinase family may also be in development.125 
Additionally, development of commercially available 
phospho-specific SGK3 antibodies for all key residues will 
be essential screening tools for both preclinical and clinical 
studies. Together, these studies paint an emerging picture of 
SGK3 as an important mediator of oncogenic signaling, and 
emphasize the critical importance of further studies focused 
on elucidating the signaling mechanisms associated with this 
kinase in both normal and malignant backgrounds.
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